Prof Jacqueline Center
Research Level
Biography
Prof Jacqueline Center qualified as an endocrinologist in 1993, obtained a Master of Epidemiology in 1995 and a PhD in 1999. She has been working on clinical and epidemiological studies related to osteoporotic fracture and its outcomes for over 18 years and has been one of the principle researchers in the Dubbo Osteoporosis Epidemiology Study. She has pioneered work on consequences of fracture including the high risk of refracture and premature mortality that has resulted in international collaborations involving investigators from several large epidemiological studies throughout Europe, Canada and the US.
She has also been involved in other areas of translational research and led one of the first set of studies that demonstrated a lack of treatment for osteoporosis following hip fracture and that improvement in treatment rates only occurred after initiation of treatment by hospital personnel and not information alone. This work has resulted in involvement in and recently chair of the Osteoporosis working group for the NSW Musculoskeletal Agency for Clinical Innovation (ACI) and the American Society for Bone and Mineral Research (ASBMR) Taskforce on Osteoporotic Fracture Secondary Prevention.
She is also involved in several national and international organizations including the Scientific Advisory Board of OsteoporosisAustralia, Research Committee of the Australian and New Zealand Bone and Mineral Society, and Editorial board member of BMC Geriatrics. As a practicing endocrinologist, primarily working in the bone field she gives regular educational talks to the general public and medical practitioners. Since 2021, she is also co-Lead of the Skeletal Diseases Program together with Prof Mike Rogers.
Prof Jacqueline Center qualified as an endocrinologist in 1993, obtained a Master of Epidemiology in 1995 and a PhD in 1999. She has been working on clinical and epidemiological studies related to osteoporotic fracture and its outcomes for over 18 years and has been one of the principle researchers in the Dubbo Osteoporosis Epidemiology Study. She has pioneered work on consequences of fracture including the high risk of refracture and premature mortality that has resulted in international collaborations involving investigators from several large epidemiological studies throughout Europe, Canada and the US.
She has also been involved in other areas of translational research and led one of the first set of studies that demonstrated a lack of treatment for osteoporosis following hip fracture and that improvement in treatment rates only occurred after initiation of treatment by hospital personnel and not information alone. This work has resulted in involvement in and recently chair of the Osteoporosis working group for the NSW Musculoskeletal Agency for Clinical Innovation (ACI) and the American Society for Bone and Mineral Research (ASBMR) Taskforce on Osteoporotic Fracture Secondary Prevention.
She is also involved in several national and international organizations including the Scientific Advisory Board of OsteoporosisAustralia, Research Committee of the Australian and New Zealand Bone and Mineral Society, and Editorial board member of BMC Geriatrics. As a practicing endocrinologist, primarily working in the bone field she gives regular educational talks to the general public and medical practitioners. Since 2021, she is also co-Lead of the Skeletal Diseases Program together with Prof Mike Rogers.
Awards and Honours
2011-2015 - NH&MRC Practitioner Fellowship
2002 - Young Investigator Award, American Society for Bone and Mineral Research
1999 - Garvan Institute of Medical Research, award for best thesis
1996 - US Endocrine Society Travel Award
1995-1998 - NH&MRC Medical Postgraduate Scholarship
1992 - RNSH Medical Staff Council Fellowship for Outstanding Achievement
1981/2 - AMSA - AMA - J. G. Hunter Research Fellowship
1981/2 - National Heart Foundation Vacation Scholarship
Education
1995 - MS Epidemiology, Harvard School of Public Health - USA
1993 - FRACP
1987 - MBBS (Hons) University of Sydney - Australia
Selected Publications
Alarkawi D, Bliuc D, Tran T, Ahmed LA, Emaus N, Bjørnerem A, Jørgensen J, Christoffersen T, Eisman JA, Center JR. Impact of Osteoporotic Fracture Type and Subsequent Fracture on Mortality: The Tromsø Study. Osteoporosis Int. 2019 (in press).
Bliuc D, Tran T, van Geel T, Adachi JD, Berger C, van den Bergh J, Eisman JA, Geusens P, Goltzman D, Hanley DA, Josse RG, Kaiser S, Kovacs CS, Langsetmo L, Prior JC, Nguyen TV, Center JR. Reduced bone loss is associated with reduced mortality risk in subjects exposed to nitrogen bisphosphonates: a mediation analysis. J Bone and Mineral Research 2019 Aug 12. doi: 10.1002/jbmr.3816. [Epub ahead of print].
Bliuc D, Tran T, van Geel T, Adachi JD, Berger C, van den Bergh J, Eisman JA, Geusens P, Goltzman D, Hanley DA, Josse RG, Kaiser S, Kovacs CS, Langsetmo L, Prior JC, Nguyen TV, Center JR. Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study. Osteoporos Int. 2019 Apr;30(4):817-828.
Nair P, Venkatesh B, Center JR. Vitamin D deficiency and supplementation in critical illness-the known knowns and known unknowns. Crit Care. 2018 Oct 29;22(1):276. doi: 10.1186/s13054-018-2185-8.
Tran T, Bliuc D, Hansen L, Abrahamsen B, van den Bergh J, Eisman JA, van Geel T, Geusens P, Vestergaard P, Nguyen TV, Center JR. Persistence of Excess Mortality Following Individual Nonhip Fractures: A Relative Survival Analysis. J Clin Endocrinol Metab. 2018 Sep 1;103(9):3205-3214.
van Geel TACM, Bliuc D, Geusens PPM, Center JR, Dinant GJ, Tran T, van den Bergh JPW, McLellan AR, Eisman JA. Reduced mortality and subsequent fracture risk associated with oral bisphosphonate recommendation in a fracture liaison service setting: A prospective cohort study. PLoS One. 2018 Jun 1;13(6):e0198006. doi: 10.1371/journal.pone.0198006. eCollection 2018.
Chen W, Simpson JM, March LM, Blyth FM, Bliuc D, Tran T, Nguyen TV, Eisman JA, Center JR. Co-morbidities only account for a small proportion of excess mortality after fracture: a record linkage study of individual fracture types. J Bone Miner Res. 2018 May;33(5):795-802.
Tran T, Bliuc D, van Geel T, Adachi JD, Berger C, van den Bergh J, Eisman JA, Geusens P, Goltzman D, Hanley DA, Josse RG, Kaiser SM, Kovacs CS, Langsetmo L, Prior JC, Nguyen TV, Center JR. Population-wide impact of non-hip non-vertebral fractures on mortality. J Bone and Miner Res 2017 Sep;32(9):1802-1810.
Center JR. Fracture burden: what two and a half decades of Dubbo Osteoporosis Epidemiology Study data reveal about clinical outcomes of osteoporosis Current Osteoporosis Reports 2017 April;15(2):88-95.
Lee P, Nair P, Eisman JE and Center JR. Bone failure in critical illness. Critical Care Medicine 2016 June 28.
Lee P, Nair P, Ng C, Slattery A, Eisman JA, Center JR. Preadmission bisphosphonate and mortality in critically ill patients. The Journal of Clinical Endocrinology & Metabolism 2016 May;101(5):1945-53. doi: 10.1210/jc.2015-3467. Epub 2016 Jan 18.
Styrkarsdottir U, Thorleifsson G, Gudjonsson SA, Sigurdsson A, Center JR et al. Sequence variants in the PTCH1 gene associate with spine bone mineral density and osteoporotic fractures. Nat Commun. 2016 Jan 6;7:10129.
Bliuc D, Nguyen ND, Alarkawi D, Nguyen TV, Eisman JA, Center JR. Accelerated bone loss and increased post-fracture mortality in elderly women and men. Osteoporos Int. 2015 Apr;26(4):1331-9.
Bliuc D, Alarkawi D, Nguyen ND, Nguyen TV, Eisman JA, Center JR. Risk of subsequent fractures and premature mortality in elderly women and men with fragility fractures without osteoporotic bone density. Journal of Bone and Mineral Research 2015 Apr;30(4):637-46.
Bliuc D, Nguyen TV, Eisman JA, Center JR. The impact of nonhip nonvertebral fractures in elderly women and men. J Clin Endocrinol Metab. 2014 Feb;99(2):415-23.
